Patients treated with IFN-beta-1a im were, according to the EDSS at study onset, in an earlier stage of MS, and it is thus conceivable that a higher endogenous IFN signature combined with IFN-beta treatment might be preferentially favorable early in disease. The gene discussed is IFNA1; the disease is myeloid sarcoma.